A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines

NCT05048342 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: LOU064

Sponsor

Novartis Pharmaceuticals